Delivery technologies for cancer immunotherapy.
Riley RS, June CH, Langer R, Mitchell MJ.
Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z.
Integrative Approaches to Cancer Immunotherapy.
Szeto GL, Finley SD.
Trends Cancer. 2019 Jul;5(7):400-410. doi: 10.1016/j.trecan.2019.05.010.
Immunotherapy: a promising approach for glioma treatment.
Yasinjan F, Xing Y, Geng H, Guo R, Yang L, Liu Z, Wang H.
Front Immunol. 2023 Sep 7;14:1255611. doi: 10.3389/fimmu.2023.1255611. eCollection 2023.
Cancer Immunotherapy-An Overview.
Kulkarni P, Do D, Shrestha S, Leach B, Salgia R.
Cancer Treat Res. 2025;129:1-16. doi: 10.1007/978-3-031-97242-3_1.
Targeting tumor-associated macrophages to synergize tumor immunotherapy.
Xiang X, Wang J, Lu D, Xu X.
Signal Transduct Target Ther. 2021 Feb 23;6(1):75. doi: 10.1038/s41392-021-00484-9.
TGFbeta biology in cancer progression and immunotherapy.
Derynck R, Turley SJ, Akhurst RJ.
Nat Rev Clin Oncol. 2021 Jan;18(1):9-34. doi: 10.1038/s41571-020-0403-1. Epub 2020 Jul 24.
Cancer immunoediting and resistance to T cell-based immunotherapy.
O'Donnell JS, Teng MWL, Smyth MJ.
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8.
Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization.
Chang Z, Guo X, Li X, Wang Y, Zang Z, Pei S, Lu W, Li Y, Huang JD, Xiao Y, Liu C.
Cell. 2025 Apr 3;188(7):1842-1857.e20. doi: 10.1016/j.cell.2025.02.002. Epub 2025 Mar 3.
Complex neural-immune interactions shape glioma immunotherapy.
Song KW, Lim M, Monje M.
Immunity. 2025 May 13;58(5):1140-1160. doi: 10.1016/j.immuni.2025.04.017. Epub 2025 May 4.
Mouse Models for Cancer Immunotherapy Research.
Olson B, Li Y, Lin Y, Liu ET, Patnaik A.
Cancer Discov. 2018 Nov;8(11):1358-1365. doi: 10.1158/2159-8290.CD-18-0044. Epub 2018 Oct 11.
